Clinical Trials Logo

Reproductive Issues clinical trials

View clinical trials related to Reproductive Issues.

Filter by:

NCT ID: NCT05290558 Recruiting - Infertility Clinical Trials

The Therapeutic Effects of Bu Shen Yi Jing Pill on Semen Quality in Sub Fertile Males: a Randomized Controlled Trial

Start date: January 7, 2022
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the safety and efficacy of Bu Shen Yi Jing (BSYJ) Pill , a type of traditional Chinese medicine, in improving male subfertility and semen parameters.

NCT ID: NCT05285605 Recruiting - Contraception Clinical Trials

Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy

Start date: March 1, 2022
Phase:
Study type: Observational

This study will entail provision of ulipristal acetate (UPA) for emergency contraception (EC) in the postpartum period for patients who have not chosen to initiate a highly effective form of contraception and study the use of EC overall as well as with regards to participants' perception of reproductive autonomy. The investigators hypothesize that providing an advance supply of EC will increase use and decrease barriers to use. Additionally, the investigators hypothesize that, with thorough EC counseling, participants will develop an increased knowledge base of EC. With increased use and knowledge, the investigators hypothesize that participants will experience greater reproductive autonomy over their contraceptive decisions.

NCT ID: NCT05066360 Completed - Epilepsy Clinical Trials

Serum Antimullerian Hormone Levels Among Epileptic Patients

Start date: July 2, 2021
Phase: N/A
Study type: Interventional

The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.

NCT ID: NCT04854707 Completed - IVF Clinical Trials

An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data

Start date: January 12, 2020
Phase:
Study type: Observational

Aim to investigate the efficacy of follitropin alpha biosimilar therapy (Primapur®) in nonselected real-world population.

NCT ID: NCT04669769 Completed - Endometriosis Clinical Trials

Retrospective Analysis of Results of Surgery for Deep Bowel Endometriosis

Start date: December 1, 2019
Phase:
Study type: Observational

identification of patients operated becaus of bowel endometriosis at the endometriosis center, University Hospital Muenster, Germany, starting 2009, Analysis of Patient history, surgical procedurie, intraoperative complications, postoperative complications, phone call assessing further complications, complaints after surgery, pregnancy, live birth, additional surgery, spontaneous conception, conception by IUI, ART

NCT ID: NCT04627805 Terminated - Contraception Clinical Trials

Evaluating MyPath to Enhance Reproductive Autonomy and Liberate Decision-making

EMERALD
Start date: November 20, 2020
Phase: N/A
Study type: Interventional

This is a pilot study to evaluate the acceptability and feasibility of incorporating a patient-facing reproductive decision support tool, MyPath, into existing clinical pathways in a SUD treatment program. This study will be conducted virtually in partnership with a single substance use treatment program within the University of Pittsburgh Medical Center (UPMC). Aim 1: Assess the feasibility and acceptability of incorporating a patient-facing reproductive decision support tool (MyPath) into existing clinical pathways in a substance use treatment program. Aim 2: Assess preliminary efficacy of MyPath on reproductive health knowledge, self-efficacy, and decisional conflict as compared to usual care, as well comparisons between receipt of reproductive health services during the usual care period versus after implementing the intervention. The investigators hypothesize that the MyPath tool is acceptable and feasible for participants and their providers within a SUD treatment program. They also anticipate that preliminary efficacy data will show a positive correlation between the MyPath intervention and receipt of reproductive services, as well as increased knowledge and self-efficacy with decreased decision conflict. This pilot study will lay the groundwork for future larger trials in order to measure efficacy of this tool in substance use treatment settings.